Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Collaborative Groups / G.I. and Other Associated Cancers Research Group / Discovered GP73 as a classifier of HCC in high risk patients and demonstrated that it improves AFP performance in detecting early stage HCC.

Discovered GP73 as a classifier of HCC in high risk patients and demonstrated that it improves AFP performance in detecting early stage HCC.

GP73 was approved for HCC screening in China in combination with AFP.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.
Announcement 09/14/2014

Thank you to everyone who helped make the 9th EDRN Scientific Workshop a success. We look forward to seeing everyone at the 28th EDRN Steering Committee Meeting from March 31-April 2, 2015, in Atlanta, GA.